Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance.

EGFR T790M mutation leads to resistance to most of clinically available EGFR TKIs. Third-generation EGFR TKIs against the T790M mutation have been in active clinical development, which includes osimertinib, rociletinib, HM61713, ASP8273, EGF816, and PF-06747775. On the other hand recently EGFR C797S mutation was reported to be a leading mechanism of resistance to the third-generation inhibitors. The C797S mutation appears to be an ideal target for overcoming the acquired resistance to the third generation inhibitors. This review summarizes the third generation inhibitors, synthesis, their mechanism of resistance and latest development on the discovery of a fourth-generation EGFR TKIs and U to Y allosteric strategies to combat the C797S EGFR resistance problem.

[1]  W. Pao,et al.  Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. , 2015, Cancer research.

[2]  Xiaodong Ma,et al.  Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer. , 2016, Journal of medicinal chemistry.

[3]  E. Cho,et al.  Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant‐specific inhibitor, in T790M‐positive NSCLC at the recommended phase II dose: 1300 , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  L. Tanoue,et al.  Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma , 2010 .

[5]  T. Clackson,et al.  Abstract 1794: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC , 2012 .

[6]  William Pao,et al.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. , 2014, Cancer discovery.

[7]  Aleksandra Markovets,et al.  Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.

[8]  M. Meyerson,et al.  BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models , 2008, Oncogene.

[9]  John R. Engen,et al.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.

[10]  A. Rossi,et al.  ALK inhibitors and advanced non-small cell lung cancer (review). , 2014, International journal of oncology.

[11]  J. Engelman,et al.  Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer , 2013, Science Signaling.

[12]  W. Pao,et al.  Acquired resistance to TKIs in solid tumours: learning from lung cancer , 2014, Nature Reviews Clinical Oncology.

[13]  G. Getz,et al.  RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer , 2015, Nature Communications.

[14]  M. Ladanyi,et al.  HER 2 Amplifi cation : A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFR T 790 M Mutation , 2012 .

[15]  G. Giaccone,et al.  Emerging protein kinase inhibitors for non-small cell lung cancer , 2013, Expert opinion on emerging drugs.

[16]  Haikuo Zhang,et al.  Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors , 2016 .

[17]  Shuhang Wang,et al.  Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer , 2016, Journal of Hematology & Oncology.

[18]  William H. Bisson,et al.  Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors , 2012, Molecular Cancer Research.

[19]  T. Mitsudomi,et al.  Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy , 2016, Cancer science.

[20]  T. Clackson,et al.  Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. , 2016, Journal of medicinal chemistry.

[21]  A. Shaw,et al.  Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase–Rearranged Non–Small Cell Lung Cancer , 2013, Clinical pharmacology and therapeutics.

[22]  William Pao,et al.  Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.

[23]  B. Cho,et al.  Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. , 2016, Lung cancer.

[24]  G. Giaccone,et al.  Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC. , 2015 .

[25]  M. Tiseo,et al.  L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  David Gilligan,et al.  Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. , 2015, The Lancet. Oncology.

[27]  Yong He.  Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[28]  J. Ahn,et al.  Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  R. Pirker.  Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer , 2016, Current opinion in oncology.

[30]  J. Barretina,et al.  EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor. , 2016, Cancer research.

[31]  William Pao,et al.  HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. , 2012, Cancer discovery.

[32]  Yan Sun,et al.  Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. , 2012, The Lancet. Oncology.

[33]  Juswinder Singh,et al.  Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. , 2013, Cancer discovery.

[34]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  F. Khuri,et al.  The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer , 2015, Cancer.

[36]  R. Bernards,et al.  Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. , 2014, Cancer discovery.

[37]  J. Yang,et al.  Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer , 2015, Current opinion in oncology.

[38]  S. Ou,et al.  Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era? , 2015, Drug design, development and therapy.

[39]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[40]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[41]  P. Jänne,et al.  EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors , 2015, Clinical Cancer Research.

[42]  J. Smaill,et al.  Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. , 2015, Journal of structural biology.

[43]  L. Sequist,et al.  The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies , 2015, Clinical Cancer Research.

[44]  L. Tanoue.  Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .

[45]  F. de Marinis,et al.  Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment , 2017, Pharmacological research.

[46]  H. Ji,et al.  Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors , 2016, Clinical Cancer Research.

[47]  G. Giaccone,et al.  A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib , 2014, Cancer.

[48]  G. Giaccone,et al.  Refining the treatment of NSCLC according to histological and molecular subtypes , 2015, Nature Reviews Clinical Oncology.

[49]  S. Peters,et al.  Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. , 2014, Cancer treatment reviews.

[50]  Matthew Grist,et al.  Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). , 2013, Journal of medicinal chemistry.

[51]  E. Giovannetti,et al.  New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong? , 2016, OncoTargets and therapy.

[52]  Hengmiao Cheng,et al.  Recent progress on third generation covalent EGFR inhibitors. , 2016, Bioorganic & medicinal chemistry letters.

[53]  Jie Yang,et al.  Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors , 2016, Journal of Biomedical Science.

[54]  Gregory Riely,et al.  Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[55]  Toshio Shimizu,et al.  ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: Preliminary results of first-in-human phase I study in Japan. , 2015 .

[56]  Chun Xing Li,et al.  Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Ce , 2016, Journal of medicinal chemistry.

[57]  L. Raez,et al.  Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation. , 2014, Lung cancer.

[58]  M. Meyerson,et al.  PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. , 2007, Cancer research.

[59]  Keunchil Park,et al.  Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer? , 2017, Current opinion in oncology.

[60]  R. Lerose,et al.  Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance , 2015, Therapeutic advances in respiratory disease.

[61]  Peter Ballard,et al.  Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. , 2014, Journal of medicinal chemistry.

[62]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[63]  L. Borsu,et al.  Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. , 2015, JAMA oncology.

[64]  Xiaoying Zhang,et al.  AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients , 2016, Molecular Cancer Therapeutics.

[65]  T. Jiang,et al.  Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer. , 2014, Translational lung cancer research.

[66]  Ryohei Katayama,et al.  Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK , 2011, Proceedings of the National Academy of Sciences.

[67]  P. Jänne,et al.  190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[68]  Zo,et al.  The Allelic Context of the C 797 S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity toSubsequent Treatment Strategies , 2015 .

[69]  K. Politi,et al.  Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer , 2015, Clinical Cancer Research.

[70]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[71]  S. Kuromitsu,et al.  Abstract 1728: ASP8273, a novel mutant-selective irreversible EGFR inhibitor, inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790M resistance mutations , 2014 .

[72]  M. Ladanyi,et al.  Characteristics of Lung Cancers Harboring NRAS Mutations , 2013, Clinical Cancer Research.

[73]  Y. Nakanishi,et al.  Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer , 2014, OncoTargets and therapy.

[74]  N. Hanna,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .

[75]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[76]  P. Jänne,et al.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.

[77]  Xiao Dong Xu,et al.  Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance , 2015, Chinese journal of cancer.

[78]  D. Planchard,et al.  EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.